Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues.

Trial Profile

Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Mar 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Feb 2015 One more end point ''Number of headache days with moderate or severe intensity'' added to the study, hence trial focus of the study also got changed to include Therapeutic use, as reported by ClinicalTrials.gov record.
    • 12 Feb 2015 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top